文献速递中医妇科中药与中成药合理使用

金凤丸改善来曲唑诱导PCOS大鼠的内分泌与卵巢功能及机制

Jinfeng Pills alleviate letrozole-induced PCOS by correcting CYP17A1/CYP19A1 steroidogenic imbalance and PI3K/Akt/mTOR-related signaling.
PubMed 文献 · J Ethnopharmacol · 2026-08-13

本研究评价金凤丸对来曲唑诱导的PCOS大鼠的作用及分子机制。结果显示,320 mg/kg金凤丸可降低睾酮和LH、恢复雌二醇并改善LH/FSH比值,增加黄体数量并减少闭锁卵泡,且未检测到肝肾毒性。网络药理学和多层分子分析提示其作用与CYP17A1/CYP19A1介导的类固醇生成、PI3K/Akt/mTOR信号及炎症-凋亡通路相关。

要点

  • 金凤丸320 mg/kg可降低PCOS大鼠睾酮和LH,恢复雌二醇水平。
  • 金凤丸增加黄体数量并减少闭锁卵泡,未检测到肝肾毒性。
  • 其机制可能与调节CYP17A1/CYP19A1、PI3K/Akt/mTOR及炎症-凋亡通路有关。

核心结论

  • 金凤丸改善来曲唑诱导PCOS大鼠的内分泌和卵巢功能障碍,其效应与调节CYP17A1/CYP19A1介导的类固醇生成、PI3K/Akt/mTOR相关信号及炎症-凋亡通路相关。

研究设计与样本

  • 采用来曲唑诱导SD大鼠PCOS模型,随后给予金凤丸160、240、320 mg/kg或二甲双胍治疗21天。
  • 评估动情周期、血清激素和卵巢形态,并进行网络药理学、卵巢蛋白质组学、qPCR、Western blot、血清代谢组学和16S rRNA肠道菌群分析。

主要发现

  • 与模型组相比,金凤丸320 mg/kg显著降低睾酮和LH,恢复雌二醇水平,并通过抑制LH改善LH/FSH比值,而FSH水平保持不变。
  • 金凤丸增加黄体数量(P = 0.0020)并减少闭锁卵泡(P = 0.0152),未检测到肝肾毒性。
  • 网络药理学和多层分子分析提示,金凤丸改善生殖内分泌紊乱和卵泡发育异常伴随CYP17A1/CYP19A1介导的类固醇生成、PI3K/Akt/mTOR相关信号及IL-17A/COX2和MAPK/ERK-p53相关炎症-凋亡通路的变化。

临床怎么用

  • 该研究为临床前证据,提示金凤丸可能改善PCOS相关生殖内分泌紊乱和卵巢组织形态异常,但直接排卵和生育结局需进一步验证。

局限性

  • 研究为大鼠模型,直接排卵和生育结局未验证,临床疗效尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Jinfeng Pills (JFP) is a classical Chinese patent medicine originating as an imperial court prescription during the Qianlong reign of the Qing dynasty (1735-1796), in continuous use in southern China and Southeast Asia for over two centuries (NMPA approval No. Z20064400). Comprising nine ingredients - Panax ginseng C.A.Mey., Cervus elaphus Linnaeus, Ligustrum lucidum W.T.Aiton, Epimedium brevicornu Maxim., Reynoutria multiflora (Thunb.) Moldenke, Leonurus japonicus Houtt., Cinnamomum cassia (L.) J.Presl, Equus asinus Linnaeus, and Curculigo orchioides Gaertn. - formulated as a honey-based pill and traditionally indicated for kidney-yang deficiency with blood stasis, its clinical presentations of oligomenorrhea and anovulatory infertility closely mirror PCOS hallmarks, yet its multi-constituent pharmacological mechanisms remain unresolved. AIM OF THE STUDY: This study aimed to evaluate the effects of JFP in a letrozole-induced PCOS rat model and explore associated molecular pathways using network pharmacology and multi-layer molecular profiling. MATERIALS AND METHODS: PCOS was induced in SD rats via letrozole, followed by 21-day JFP treatment (160, 240, 320 mg/kg) or metformin. Estrous cyclicity, serum hormones, and ovarian morphology were evaluated. Network pharmacology, ovarian proteomics, qPCR, Western blot, serum metabolomics, and 16S rRNA gut microbiota profiling were performed as complementary analyses. RESULTS: Compared with the model group, JFP at 320 mg/kg, the most effective dose among the tested doses, significantly reduced testosterone and LH, restored estradiol levels, and improved the LH/FSH ratio mainly through LH suppression, while FSH levels remained unchanged. JFP also increased corpus luteum number (P = 0.0020) and reduced atretic follicles (P = 0.0152), with no detectable hepatorenal toxicity. Network pharmacology and multi-layer molecular profiling, supported by qPCR and Western blot validation, suggested that JFP-associated improvements in reproductive endocrine disturbance and follicular developmental abnormalities were accompanied by changes in CYP17A1/CYP19A1-mediated steroidogenesis, PI3K/Akt/mTOR-related signaling, and IL-17A/COX2-and MAPK/ERK-p53-associated inflammatory-apoptotic pathways. CONCLUSION: JFP improved endocrine and ovarian dysfunction in letrozole-induced PCOS rats, with its effects associated with modulation of CYP17A1/CYP19A1-mediated steroidogenesis, PI3K/Akt/mTOR-related signaling, and inflammatory-apoptotic pathways. These findings provide preclinical evidence and mechanistic clues for further investigation of JFP in PCOS-related reproductive endocrine disturbance and ovarian histomorphological abnormalities, while direct ovulation and fertility outcomes require further validation.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Li H, Chen M, Deng S, et al. Jinfeng Pills alleviate letrozole-induced PCOS by correcting CYP17A1/CYP19A1 steroidogenic imbalance and PI3K/Akt/mTOR-related signaling. J Ethnopharmacol. 2026. PMID: 42595065. doi:10.1016/j.jep.2026.122268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。